Universal carrier for targeting molecules to gb3 receptor expressing cells
CA 2435712 C · Owner: Universite Pierre Et Marie Curie (Paris Vi) · Inventors: Goud, Bruno; Johannes, Ludger; Tartour, Eric
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention concerns an universal polypeptidic carrier for targeting directly or indirectly a molecule to Gb3 receptor expressing cells and having the following formula STxB-Z(n)-Cys, wherein: STxB is the Shiga Toxin B subunit or a functional equivalent thereof Z is an amino-acid devoided of , sulfydryl group n being 0, 1 or a polypeptide, Cys is the amino-acid Cysteine, and the use thereof for MHC class I and MHC class II presentation of antigens.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 1, 2002 and granted July 10, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 1, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 1, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.